menu
    • menu
    [{"orgOrder":0,"company":"Grunenthal","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grunenthal \/ Teva Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal \/ Teva Pharmaceutical"},{"orgOrder":0,"company":"Grunenthal","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Rosuvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Grunenthal","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Grunenthal \/ Gr\u00fcnenthal","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal \/ Gr\u00fcnenthal"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Grunenthal \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal \/ Not Applicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Rosuvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Grunenthal","amount2":0.34999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Grunenthal \/ Gr\u00fcnenthal","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal \/ Gr\u00fcnenthal"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"8","companyTruncated":"Grunenthal \/ Grunenthal"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Grunenthal \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal \/ Not Applicable"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Averitas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Mesoblast","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Grunenthal"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Grunenthal","amount2":0.51000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.51000000000000001,"dosageForm":"Injection","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal \/ Grunenthal"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Rheumatology","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Grunenthal \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Not Applicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Grunenthal","amount2":0.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.5,"dosageForm":"Injection","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal \/ Grunenthal"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal \/ Grunenthal"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Rheumatology","graph2":"Phase III","graph3":"Grunenthal","amount2":0.67000000000000004,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.67000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"Grunenthal \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal \/ Shionogi"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"4","companyTruncated":"Grunenthal \/ Grunenthal"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Grunenthal Meds","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Fentanyl","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Grunenthal","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal \/ Grunenthal"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Valinor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Naloxegol Oxalate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Grunenthal","amount2":0.25,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Grunenthal \/ Grunenthal","highestDevelopmentStatusID":"14","companyTruncated":"Grunenthal \/ Grunenthal"}]

    Find Clinical Drug Pipeline Developments & Deals by Grunenthal

    Menu

    Grunenthal

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naloxegol Oxalate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Recipient : Valinor Pharma

                            Deal Size : $250.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Grünenthal Continues US Growth Push with $250M Acquisition of Valinor Pharma

                            Details : Through the acquisition, Grunenthal will leverage the Valinor pipeline, which also includes Movantik (naloxegol), indicated for the treatment of OIC in adult patients with chronic non-cancer pain.

                            Brand Name : Movantik

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 22, 2024

                            Lead Product(s) : Naloxegol Oxalate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Recipient : Valinor Pharma

                            Deal Size : $250.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Grunenthal Meds

                            Deal Size : $83.2 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Grünenthal, Kyowa Kirin International Enter Joint Venture Collaboration

                            Details : The joint venture collaboration comprises 13 brands across 6 therapeutic areas primarily focused on pain management, including Abstral (fentanyl) and PecFent for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3® for osteo...

                            Brand Name : Abstral

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 02, 2023

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Grunenthal Meds

                            Deal Size : $83.2 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Catalent Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Catalent and Grünenthal Announce Successful Collaboration to Facilitate Expedited Clinical Development Timeli...

                            Details : The collaboration leads to the successful reformulation of an investigational, orally dosed small molecule in Grünenthal’s pipeline to improve its bioavailability. Phase 1 studies of the molecule will be supported by using the Catalent Xpress Pharmace...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 15, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Catalent Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Grunenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfo...

                            Details : Key products in the portfolio include Abstral® and PecFent® (Fentanyl) for breakthrough cancer pain, Moventig® (Naloxegol) for opioid-induced constipation and Adcal-D3® (calcium and vitamin D3) for osteoporosis.

                            Brand Name : Abstral

                            Molecule Type : Small molecule

                            Upfront Cash : $82.7 million

                            November 24, 2022

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone Undecanoate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Recipient : Bayer AG

                            Deal Size : $498.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Grünenthal Closes Deal To Acquire Testosterone Therapy Nebido™ From Bayer For €495 Million

                            Details : Nebido (having testosterone undecanoate) is the only available injectable long-acting depot preparation of testosterone undecanoate, developed for the treatment of male hypogonadism.

                            Brand Name : Nebido

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 02, 2022

                            Lead Product(s) : Testosterone Undecanoate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Recipient : Bayer AG

                            Deal Size : $498.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiniferatoxin

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Grünenthal Starts Phase III Trials for Resiniferatoxin in Osteoarthritis-Related Pain

                            Details : RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis.

                            Brand Name : RTX

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 18, 2022

                            Lead Product(s) : Resiniferatoxin

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiniferatoxin

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Shionogi

                            Deal Size : $670.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Grünenthal to License Osteoarthritis Pain Treatment to Shionogi in Japan in Deal of up to > $ 500 Million

                            Details : The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX (resiniferatoxin) to Shionogi will be carried out exclusively by Grünenthal.

                            Brand Name : RTX

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 04, 2022

                            Lead Product(s) : Resiniferatoxin

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Shionogi

                            Deal Size : $670.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Testosterone Undecanoate

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Recipient : Bayer AG

                            Deal Size : $506.6 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Grünenthal Acquires Testosterone Treatment Nebido™ From Bayer

                            Details : Nebido (testosterone undecanoate) is used for male hypogonadism. It is used for treating clinical symptoms such as regression of secondary sexual characteristics, change in body composition, asthenia, reduced libido or erectile dysfunction due to low tes...

                            Brand Name : Nebido

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 14, 2022

                            Lead Product(s) : Testosterone Undecanoate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Recipient : Bayer AG

                            Deal Size : $506.6 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed

                            Grunenthal

                            Germany arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rexlemestrocel-L,Hyaluronic Acid

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Mesoblast

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA’s OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Progra...

                            Details : A key objective of MPC-06-ID (rexlemestrocel-L) is to demonstrate reduction in pain and opioid usage and and position rexlemestrocel-L as a potential opioid-sparing agent.

                            Brand Name : MPC-06-ID

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 15, 2021

                            Lead Product(s) : Rexlemestrocel-L,Hyaluronic Acid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Mesoblast

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Averitas Pharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Averitas Pharma

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Enrolled in a Phase III study with QUTENZA® in Post-Surgical Neuropathic Pain

                            Details : The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.

                            Brand Name : Qutenza

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 10, 2021

                            Lead Product(s) : Capsaicin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth